About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, January 9th, 2018

The QualityStocks
Daily Stock List


Lithium Corp. (LTUM)

Breaking Bulls, OTCPicks, SmarTrend Newsletters, PickPennyStocks, FNNO Newsletters, AllPennyStocks, Stockpalooza, Canadian Microcap Report, and Stockdigest Report reported previously on Lithium Corp. (LTUM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Lithium Corp. engages in the identification, acquisition, and exploration of metals and minerals with an emphasis on lithium mineralization on properties in Nevada. The Company’s commitment is to the exploration for energy storage related resources across North America, looking to capitalize on opportunities within the growing next generation energy storage markets. An exploration stage mining company, Lithium is headquartered in Elko, Nevada.

The Company maintains a strategic alliance with Altura Mining. Lithium’s flagship property is Fish Lake Valley. At Fish Lake Valley, it holds Placer claims that cover roughly 7,800 acres. The Fish Lake Valley Property is in northern Esmeralda County in west-central Nevada.

In north-western Nevada, Washoe County, Lithium has its San Emidio Project. The Company staked a block of claims in the San Emidio Valley during September of 2011, and presently holds 1,600 acres.

Additionally, it has its North Big Smokey lithium brine exploration property in Big Smokey Valley, Nye County, Nevada. This property is on federal lands. It consists of 44 association placer claims, most which are 80 acres. In total the prospect is approximately 3,400 acres.

Lithium has its BC Sugar Property situated in Shuswap, B.C. It has assembled a 19,816-acre (8,019 hectare) block of mineral claims in B.C. that is highly prospective for hosting commercially extractable deposits of flake graphite.

Furthermore, the Company has its Hughes Property in Tonopah, Nevada. Lithco participated in the establishment of Summa LLC, a private Nevada Limited Liability company that holds 88 fee-title patented lode claims that cover about 1,191.3 acres of prospective mineral lands. Lithium signed a Joint Operating Agreement with the other participants to govern the conduct of Summa, and the development of the lands.

This past October, Lithium announced that it recently excavated a ''mini bulk'' sample at its BC Sugar flake graphite prospect in B.C. This sample was submitted to SGS Lakefield's laboratory in Burnaby, B.C.

Elsewhere in B.C, the Company has ended work on the Bormal option properties. It is now awaiting final assay results from these new Rare Earth Element/Tantalum-Niobium prospects. The results will include further assays from a zone discovered in July 2017 where initial assays indicated Total Rare Earth Element (TREE) content was up to 0.75 percent.

In December, Lithium announced that Summa LLC, which Lithium owns a 25 percent interest in, recently entered into an agreement where it will sell a 100 percent interest (subject to a ½ percent Net Smelter Royalty or NSR) in the 20-acre Copper Chief patented mineral claim in Nevada for $103,000. Moreover, Summa received an offer to option its other four patented claims in the Goodsprings Mining District.

Lithium’s President, Mr. Tom Lewis, is a Managing Member of Summa, which holds manifold properties across Nevada, which originated from Howard Hughes’s Summa Corporation.

Lithium Corp. (LTUM), closed Tuesday's trading session at $0.46, down 2.34%, on 1,530,531 volume with 350 trades. The average volume for the last 60 days is 890,965 and the stock's 52-week low/high is $0.046/$0.535.

Probe Metals, Inc. (PROBF)

OTC Markets, Stockhouse, MarketWatch, InvestorsHub, Morningstar, Barron’s, The Street, Northern Miner, PennyStockHub, Junior Mining Network, Agoracom, 4-Traders, Investopedia, Investing, Macroaxis, Marketwired, and Barchart reported on Probe Metals, Inc. (PROBF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Incorporated in 2015, Probe Metals, Inc. engages in the acquisition, exploration, and development of gold properties. The Company controls a strategic land package of greater than 1,000-square-kilometers of exploration ground within some of the most prolific gold belts in Quebec - Val d’Or, est Timmins, Casa-Berardi, and Detour Quebec.

Listed on the OTC Markets Group’s OTCQB, Probe Metals has its head office in Toronto, Ontario. The Company was established due to the sale of Probe Mines Limited to Goldcorp in March of 2015. Goldcorp presently owns an approximately 13.7 percent stake in Probe Metals.

The Company’s key asset is the Val-d’Or East Gold Project in Quebec. The Val-d'Or East Project consists of the Pascalis, Lapaska, and Megiscane-Tavernier Properties. The Val d'Or East Project consists of 293 claims totaling 11,904 hectares of land, controlled by Probe Metals, positioned roughly 25 kilometers east of the city of Val-d'Or in Quebec.

The Company also has its Detour Quebec Project. This project includes 100 percent owned properties and the 75 percent Probe-SOQUEM JV (Joint Venture) properties.

Probe Metals other Projects include the Dubuisson property in Dubuisson Township, Quebec; and the Timmins West in Ontario (the Meunier-144 JV property is in the western part of the prolific Timmins gold camp).

Other Projects also include the Casa Cameron Project in Quebec. This Project includes properties situated north of La Sarre, Amos and Lebel-sur-Quevillon, in the northwest region of Quebec.

Probe Metals also has its Black Creek Chromite Project in Ontario. The Black Creek Chromite deposit is in the James Bay Lowlands in a region known as "The Ring of Fire".

In July 2017, Probe Metals announced it completed the earlier disclosed asset purchase of the Aurbel East property from QMX Gold Corporation. This Property is located immediately adjacent to Probe’s Val-d'Or East Project near Val-d'Or, Quebec.

This past October, Probe Metals announced the completion of the earlier announced acquisition of the Courvan property from Monarques Gold Corporation. Probe’s landholdings in Val-d’Or are now 327 square kilometers. This makes it one of the largest consolidated land packages in the Val-d'Or Mining Camp.

Last month, Probe Metals announced the completion of the sale of the West Porcupine property to GFG Resources, Inc. Probe sold a 100 percent interest in the property to GFG in exchange for the issuance of 6,477,883 common shares of GFG. This represents a value of $3.5 million based on GFG Resources’ 20-day volume weighted average share price (VWAP) ending December 7, 2017.

Yesterday, Probe Metals provided new results from the 2017 drill program at its 100 percent owned Val-d’Or East project. Last year, Probe drilled 83,076 meters in 194 holes at Val-d’Or East. This drill program concentrated on expansion and exploration drilling in and around the New Beliveau gold deposit and also on other gold zones along a 2.5 kilometer strike length within the Pascalis Gold Trend.

Results from 38 holes (PC-17-198 to PC-17-235) totaling 16,104 meters drilled along the Pascalis Gold Trend continue to demonstrate strong potential for expansion and new discoveries surrounding the former Beliveau mine.

Expansion drilling in the Main dyke 300 meters to the south returned major results with intercepts grading 3 g/t Au over 83.1 meters starting at 7 meters depth. This includes 5.3 g/t Au over 13.6 meters, 5.9 g/t Au over 5.5 meters and 10.8 g/t Au over 11.4 meters in Hole PC-17-207.

Mr. David Palmer, Probe Metals’ President and Chief Executive Officer, stated, “It is encouraging to see such strong drilling results from New Beliveau as we finish 2017 and start the 2018 drill program. The success of the drilling at New Beliveau to-date bodes well for continued expansion in the drilling ahead. In addition to the achievements at New Beliveau, 2017 also saw an expansive regional exploration program that has generated a significant number of priority drill targets, all in areas that have seen very little historic exploration.”

Probe Metals, Inc. (PROBF), closed Tuesday's trading session at $1.1596, down 1.73%, on 1,000 volume with 1 trade. The average volume for the last 60 days is 59,753 and the stock's 52-week low/high is $0.95/$1.4233.

Surna, Inc. (SRNA)

PHUB News, Actual Gains, Hot Stock Profits, PennyStockRumors.net, DSR News, PricelessPennyStocks, Value Penny Stocks, Ascending Stocks, Promotion Stock Secrets, Wall Street Mover, TopPennyStockMovers, Marketbeat, CFN Media Group, Cannabis Financial Network News, SmallCapVoice, Greenbackers, OTC Stock Review, and Market Wire Stocks reported on Surna, Inc. (SRNA), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Surna, Inc. develops, acquires, produces, and sells equipment for the legal marijuana industry. It develops inventive technologies and products to monitor, control, and address the energy and resource intensive nature of indoor cannabis cultivation. The Company’s mission is to acquire intellectual property (IP) and scalable operating companies in the nascent, legal marijuana industry with a focus on disruptive technology, equipment, as well as related support services. Surna’s goal is to dominate the infrastructure, growing, and support side of the international cannabis industry. Surna is based in Boulder, Colorado.

The Company develops leading-edge technologies and products. The basis of its present revenue stream is on its main product offerings - supplying industrial technology and products to commercial indoor cannabis grow facilities. By way of its wholly-owned subsidiary, Hydro Innovations, Surna provides a complete line of commercial and small business indoor agriculture equipment.

A technology business, Surna engineers, manufactures, and distributes state-of-the art equipment and systems for Controlled Environment Agriculture (CEA). Currently, its specialty is commercial indoor cannabis cultivation. Its business model excludes the production or sale of marijuana.

The Company has its signature water-cooled climate control platform. Surna has filed a provisional patent application covering enhancements to its proprietary Climate Control Systems and Methods used in indoor gardens. The patent covers an industrial process that provides electricity, heating, and cooling while using the resulting carbon-dioxide (CO2) produced as a nutrient for the plants.

Surna’s intention is to integrate this and other proprietary technology into a new, commercial-grade power-generating and environmental control system product. The system is undergoing design to provide a near zero waste energy alternative for the cannabis industry.

This past November, Surna announced operating and financial results for the three and nine months ended September 30, 2017. Select highlights include Revenue for the three months ended September 30, 2017 of $1,566,000. This represents an increase of $395,000, or 34 percent, versus the three months ended September 30, 2016.

The Company had an Operating Loss of $1,234,000 for the three months ended September 30, 2017 that includes $626,000 of non-cash, equity-based compensation expenses. During the three months ended September 30, 2017, Surna was awarded new sales contracts totaling $2,385,000, bringing the Company’s total new sales contracts awarded for the nine months ended September 30, 2017 to $7,182,000.

Last month, Surna announced that it completed a private placement offering of investment units, at a price of $0.12 per unit, with certain accredited investors. Surna issued 14,734,000 units for aggregate proceeds of $1,768,080.

Chris Bechtel, Surna’s CEO, said, "Surna has recently expanded both its sales and project management teams with key hires, with the objective of ramping organic growth over the next 24 months, and this private placement will help further accelerate that growth plan."

Surna, Inc. (SRNA), closed Tuesday's trading session at $0.345, up 24.82%, on 3,372,859 volume with 944 trades. The average volume for the last 60 days is 1,075,957 and the stock's 52-week low/high is $0.0912/$0.2999.

Kaya Holdings, Inc. (KAYS)

OTC Markets, Daily Marijuana Observer, Barchart, Equity Clock, Stockhouse, Stockflare, TipRanks, Zacks, The Street, and Microcap Daily reported on Kaya Holdings, Inc. (KAYS), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Kaya Holdings, Inc., via subsidiaries, produces, distributes and sells legal premium medical and recreational cannabis products. These include flower, concentrates and oils, and cannabis-infused foods. The Company was previously known as Alternative Fuels America, Inc. It changed its corporate name to Kaya Holdings, Inc. in April of 2015. The Company’s shares trade on the OTCQB. Kaya Holdings is based in Fort Lauderdale, Florida.

The Company is the first fully reporting U.S. public company to own and operate a vertically integrated seed-to-sale legal marijuana enterprise in the U.S. In January of 2014, Kaya Holdings incorporated a subsidiary, Marijuana Holdings Americas, Inc., a Florida corporation (MJAI). Via entities controlled by MJAI, Kaya concentrates on opportunities in the legal recreational and medical marijuana sectors in the U.S.

The Company applied for and was awarded its first license to operate a Medical Marijuana Dispensary in March of 2014. It developed the Kaya Shack™ brand for its retail operations. On July 3, 2014, it opened its first Kaya Shack™ Medical Marijuana Dispensary in Portland, Oregon. In April of 2015, Kaya started its own medical marijuana grow operations for the cultivation and harvesting of legal marijuana.

Kaya Holdings now operates three Kaya Shack™ OLCC ( Oregon Liquor Control Commission) licensed marijuana retail stores to service the legal medical and recreational marijuana market in Oregon. At present, store number four is under construction.

Furthermore, Kaya recently acquired a 26 acre parcel that it has targeted for development of the Kaya Farms™ Medical and Recreational Marijuana Grow and Manufacturing Complex.

In November 2017, Kaya Holdings announced that it retained the services of the Willard C. Dixon Architect, LLC, architectural design firm of Eugene, Oregon, to design and assist with developing Kaya’s cultivation and manufacturing facilities on its newly acquired 26 acre property in Lebanon, Oregon.

Willard C. Dixon & Associates will assist Kaya with the initial site layout and design of the Kaya Farms™ Marijuana Grow and Manufacturing Facility. This includes securing all necessary permits, creating construction documents, and overseeing construction of cost-effective, energy efficient structures.

In December, Kaya Holdings announced that it completed the processes required to launch its own home delivery service in Portland and Salem, Oregon. It expects to operate four cars initially, with more cars to be added as demand requires and as the Company expands into other cities in Oregon.

Kaya Holdings is planning execution of its stated business goals in accordance with current understanding of State and Local Laws and Federal Enforcement Policies and Priorities as it relates to Marijuana (as outlined in the Justice Department's Cole Memo dated August 29, 2013). The Company plans to proceed cautiously with respect to legal and compliance issues.

Kaya Holdings, Inc. (KAYS), closed Tuesday's trading session at $0.195, down 2.50%, on 550,581 volume with 162 trades. The average volume for the last 60 days is 680,341 and the stock's 52-week low/high is $0.10/$0.453.

RegeneRx Biopharmaceuticals, Inc. (RGRX)

PennyStockProphet, Penny Pick Finders, Planet Penny Stocks, Buzz Stocks, Stock Onion, Stock News Now, TopPennyStockMovers, and SmarTrend Newsletters reported earlier on RegeneRx Biopharmaceuticals, Inc. (RGRX), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company. It centers on tissue protection, repair, and regeneration with a wide-ranging portfolio of product candidates for first-in-class therapeutic peptides. The Company’s mission is to research and develop novel pharmaceuticals, which protect and repair tissue and organ damage caused by disease, trauma, or other pathology. RegeneRx Biopharmaceuticals is headquartered in Rockville, Maryland.

The Company holds manifold issued patents or filed patent applications worldwide to enable and protect numerous indications and applications for its product candidates. At present, RegeneRx has three drug candidates in clinical development for ophthalmic, cardiac, and dermal indications.

Furthermore, the Company has three active strategic licensing agreements in the U.S, China, and Pan Asia (Korea, Japan, and Australia, among others). In addition, RegeneRx has patents and patent applications covering its products in many nations globally.

RegeneRx Biopharmaceuticals is concentrating on moving three distinct Tβ4-based drug candidates through the clinic. These are RGN-137, RGN-259, and RGN-352. RGN-137 is a topical gel formulation of the peptide Tβ4. The Company is developing this as a novel treatment to expedite dermal healing. RGN-137 is a Tβ4-based dermal gel formulation undergoing development for epidermolysis bullosa, which is a rare skin condition.

RegeneRx Biopharmaceuticals is focusing on the development of Thymosin beta 4 (a novel therapeutic peptide), for tissue and organ protection, repair and regeneration. RGN-259, its TB4-based ophthalmic drug candidate, has been designated an orphan drug for the treatment of neurotrophic keratopathy (NK), which is a primary focus of RegeneRx’s clinical development efforts in the U.S.

RegeneRx is also developing RGN-352. RGN-352 is its TB4-based injectable. This is a Phase 2-ready drug candidate designed to be administered systemically to prevent and repair cardiac damage resulting from heart attacks and central nervous system tissue damage associated disorders. These include peripheral neuropathy, multiple sclerosis and traumatic brain injuries - including stroke.

This past November, RegeneRx Biopharmaceuticals announced that Thymosin beta 4 (Tβ4), the active ingredient in RGN-259, a preservative-free ophthalmic eye drop, was the subject of a Keynote Address at the 5th International Symposium of Thymosins in Health and Disease in Washington, DC. The presentation was given by Dr. Gabriel Sosne, an award-winning clinician scientist, Associate Professor in Ophthalmology and Anatomy and Cell Biology at Wayne State University School of Medicine, and a clinician at the Kresge Eye Institute in Detroit, Michigan.

RegeneRx Biopharmaceuticals, Inc. (RGRX), closed Tuesday's trading session at $0.22, even for the day, on 95,568 volume with 18 trades. The average volume for the last 60 days is 103,662 and the stock's 52-week low/high is $0.139/$0.38.

US Cobalt, Inc. (USCFF)

InvestorsHub, Stockhouse, OTC Markets, Investors Hangout, 4-Traders, Dividend Investor, TradingView, Macroaxis, and Simply Wall St. reported on US Cobalt, Inc. (USCFF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

US Cobalt, Inc. focuses on the acquisition and development of high grade cobalt. The Company’s key assets are situated in Idaho, Utah, and the Province of Alberta. An exploration company, US Cobalt is headquartered in Vancouver, British Columbia. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Cobalt’s uses vary from aircraft engines to its chief use in rechargeable batteries, including Tesla’s Lithium Ion Batteries. Battery production accounts for 49 percent of cobalt demand (Source: Darton Commodities). Cobalt is frequently found alongside copper. More than 10 percent of cobalt production is presently offline resulting from closures because of weak copper and nickel prices.

US Cobalt has its Iron Creek Cobalt (Lemhi County, Idaho), Paradox Basin Lithium (Utah), and Deep Valley Lithium (Alberta) Projects. The Iron Creek Cobalt Project benefits from a considerable amount of historical exploratory work. This includes about 30,000 feet of diamond drilling, and the mining of 1,500 feet of underground workings.

The Iron Creek Cobalt Property covers 1,797 acres in 90 lode mining claims. This includes 7 patented claims totaling 137 acres, and 83 unpatented claims totaling 1,660 acres. Roughly 30,000 feet of diamond drilling and 2,000 feet of underground drifting has been completed at the Iron Creek Cobalt Property.

The Paradox Property comprises 111 mineral claims encompassing roughly 2,220 acres, which contain eight historic oil and gas drill holes. The Paradox Property is roughly 4 kilometers northwest of Intrepid Potash’s Cane Creek Operation. It is contiguous to the north of Voltaic Minerals Corp.’s “Green Energy” lithium property.

The Deep Valley Lithium Property is in the Fox Creek- Sturgeon Lake area of west-central Alberta. This Property covers 6,648 ha (16,427 acres) and is about 55 kilometers due west of the community of Fox Creek.

US Cobalt’s aggressive exploration program started in June of 2017. It paused for the holiday break at the end of the second week of December. It will re-start this month. The design of the Program is to assess the historic mineralization over a strike length of 1600 feet and to a depth of 600 to 700 feet.

As of early December 2017, US Cobalt was planning the winter 2018 exploration program.

Mr. Wayne Tisdale, US Cobalt’s Chief Executive Officer, said, “Exploration at the Iron Creek Project has moved at a rapid pace since field activities began early this summer… The Company's progress during the first full year of field activities are expected to bring the project to a stage which would commonly require five years to complete. We are excited to commence work on the first modern resource estimate upon receipt of all analytical results from the 2017-18 drilling campaign."

US Cobalt, Inc. (USCFF), closed Tuesday's trading session at $0.5351, up 7.71%, on 141,489 volume with 59 trades. The average volume for the last 60 days is 80,830 and the stock's 52-week low/high is $0.17/$0.88.

Nemus Bioscience, Inc. (NMUS)

MarketWatch, InvestorsHub, OTC Markets, and Zacks reported on Nemus Bioscience, Inc. (NMUS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A biopharmaceutical company, Nemus Bioscience, Inc. centers on the discovery, development, and commercialization of cannabinoid-based therapeutics for significant unmet medical needs in worldwide markets. The Company’s strategy will explore the use of natural and synthetic compounds, alone or in combination. A highly qualified team of executives with decades of biopharmaceutical experience and significant background in early-stage drug development leads Nemus Bioscience. OTCQB-listed, the Company has its head office in Costa Mesa, California.

Using certain proprietary technology licensed from the University of Mississippi, Nemus Bioscience is working to develop novel ways to deliver cannabinoid-based drugs for specific indications. Its goal is optimizing the clinical effects of such drugs, while limiting the potential adverse events.

Cannabinoids are a class of chemically diverse compounds, which undergo extraction from the cannabis plant. These compounds express their physiological response through binding to specific cannabinoid receptors (CB1 and CB2) that are found throughout the body. Cannabinoids can specifically have impacts on the immune system, nervous system, as well as the body’s organs.

Nemus develops novel and proprietary classes of product candidates. The design of these are to improve therapeutic options by way of enhanced chemical engineering, which allow drug candidates to have more predictable bioavailability and pharmacokinetics leading to optimized efficacy and safety.

Nemus Bioscience brings proprietary bioengineering to cannabinoid-based therapeutics to optimize therapeutic targeting. At present, the Company is the only partner of the University of Mississippi for the development and commercialization of these bioengineered cannabinoid-based drug candidates.

Nemus Bioscience is presently the only cannabinoid drug developer advancing a bioengineered multi-cannabinoid drug platform for the treatment of ocular diseases such as glaucoma. The Company is currently the only cannabinoid drug developer advancing a bioengineered multi-cannabinoid drug platform for the treatment and management of infectious diseases.

Additionally, Nemus is currently the only cannabinoid drug developer employing biosynthetic approaches for the manufacturing of Nemus Bioscience drug products.

Recently, Nemus Bioscience announced that it entered into agreements with Emerald Health Sciences, Inc., including a binding term sheet, Secured Promissory Note for a convertible loan and a Security Agreement. The Bridge Loan provides for aggregate gross proceeds to Nemus Bioscience of up to $900,000. It is secured by all of Nemus’ assets. Nemus received proceeds of $500,000 on December 28, 2017. The agreements provide for the funding of the remaining $400,000 on January 16, 2018.

Nemus Bioscience, Inc. (NMUS), closed Tuesday's trading session at $0.215, even for the day, on 440,268 volume with 87 trades. The average volume for the last 60 days is 216,299 and the stock's 52-week low/high is $0.10/$0.50.

Emerald Medical Applications Corp. (MRLA)

OTC Markets, MarketWatch, and YCharts reported on Emerald Medical Applications Corp. (MRLA), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Emerald Medical Applications Corp. is a medical technology company based in Petach Tikva, Israel. It utilizes proprietary military image processing technology and state-of-the-art data analytics to improve the analysis of medical images. The Company engages in the development and sale of DermaCompare™. This is its proprietary Artificial Intelligence (AI) technology and application for the early diagnosis of melanoma and other skin cancers. Emerald Medical Applications lists on the OTC Markets’ OTCQB.

Emerald Medical Applications was awarded the Grand Prize of 500,000 Euros over 3,500 other competing technology companies at Publicis Groupe's "Publicis 90" Initiative at the Viva Technology event held in Paris, France in early July of 2016.

DermaCompare is the first application of the Company’s technology and innovation. Its technology uses the knowledge of military image processing and big data analytics to improve the analysis of medical images for the benefit of patients and the medical community. DermaCompare is a Food and Drug Administration (FDA) Class #1 approved, HIPPA-compliant, skin cancer (melanoma) screening platform.

DermaCompare enables patients to self-conduct a dermatology scan utilizing Total Body Photography Imaging (TBP) taken with a digital camera, typically a tablet or Smartphone (iPhone or Android). The application (App) and instructions can be downloaded on almost any device with a digital camera.

DermaCompare provides actionable pieces of information, higher quality with reduced costs. It is aligned with population health management initiatives taken by governments around the world.

DermaCompare enables home use by using every Smartphone. It applies AI and predictive analytics, and maps the ‘Melanoma Starting Point’. DermaCompare is a pioneering skin cancer screening platform. It enables physicians to identify and monitor changes in their patients’ skin characteristics.

Upon a patient uploading their TBP images to their file in the DermaCompare cloud for storage and review, the DermaCompare platform compares those images to any prior patient images on file, as well as any relevant images from Emerald’s database. The DermaCompare platform also updates the patient file and creates a summary of data points with current, relevant data pertaining to the patient's skin images together with alerts to any suspicious image changes.

In addition, the DermaCompare platform notifies the associated physician to retrieve and review the patient's chart and TPB images. DermaCompare integrates augmented reality. This allows physicians to review the patient’s skin, using their smartphone or Google Glass.

The platform will provide for the first time a global multi-dimensional database of the human skin accessible anytime, anywhere. The Company’s technology originated from the concepts applied by the Israeli Air Force and the intelligence services that employ auto aerial photo diagnostics to track collateral damage after engaging the enemy.

Emerald Medical Applications Corp. (MRLA), closed Tuesday's trading session at $0.152, up 44.21%, on 433,502 volume with 64 trades. The average volume for the last 60 days is 42,995 and the stock's 52-week low/high is $0.0125/$0.32.


The QualityStocks
Company Corner


Tapinator, Inc. (TAPM)

The QualityStocks Daily Newsletter would like to spotlight Tapinator, Inc. (TAPM). Today, Tapinator, Inc. closed trading at $0.3454, up 15.13%, on 824,250 volume with 231 trades. The stock’s average daily volume over the past 60 days is 172,949 and its 52-week low/high is $0.0711/$0.35.

Mobile gaming in particular is a promising segment for blockchain adoption, with the fastest growing rate in the whole gaming industry and over $40 billion in revenues in 2017. Tapinator, Inc. (TAPM) has positioned itself to exploit these market trends and establish an early lead within the blockchain gaming industry through the recent creation of its subsidiary, Revolution Blockchain LLC.

Tapinator, Inc. (TAPM) is a developer and publisher of mobile games on the iOS, Google Play and Amazon platforms. The Company's portfolio includes over 300 mobile gaming titles generating hundreds of thousands of daily player downloads that provide predictable and attractive returns through the sale of branded advertisements and consumer app store transactions. Tapinator, based in New York and with product development teams located throughout the world, was founded in 2013 by a visionary team that has been building mobile games and applications since 2007 and has achieved multiple successful exits.

Tapinator's business strategy includes the creation of a select number of best-in-class Full-Featured Games, such as ROCKY™ and Solitaire Dash, which provide game players with more in-depth, unique content that supports long-term retention and generates higher investment returns. The Full-Featured Games model creates the potential for sustainable $100+ million franchise-type games that have product lifespans of at least five years. Tapinator uses a proprietary set of dynamic development and marketing processes factored upon gaming category, estimated player retention and projected player profitability.

Recent successful launches of two new Full-Featured titles – Big Sport Fishing 2017 and Dice Mage 2 – were recognized on the Apple iOS platform as "New Games We Love." During the game's first seven days after global release, Big Sport Fishing 2017 received well over 520,000 player downloads. Four new titles, ColorFill, Divide & Conquer, Shadowborne and Fusion Heroes, are in the pipeline for release in Q4 2017 and Q1 2018 as well. The formula for these game combines proven gameplay elements with best-in-class monetization systems, supplemented by Tapinator's strong creative team of developers, strategists and product specialists. The company's Rapid-Launch Games division also saw increasing player interest recently with the launch of Fidget Spinner Superhero and Scary Shark Evolution 3D.

Tapinator's diversified revenue sources includes 54 percent from advertising placed within its mobile games and 46 percent from consumer app store purchases. The Company limits advertising placements to between game levels and also runs rewarded video ad units that are tied directly into the game's currency. Tapinator's portfolio includes more than 300 active titles, with no single game accounting for more than 25 percent of total revenues during the first half of 2017.

As Tapinator looks toward the future, opportunities in Virtual Reality (VR) and Augmented Reality (AR) show great promise. The company has released several prototype VR games to gather data before pursuing a more significant VR product. Recent market reports suggest that the VR industry will hit $30 billion by 2020 and the AR industry will surpass that with a projected $120 billion. Tapinator also plans to pursue publishing transactions that leverage its network, platform relationships and operational excellence. Significant opportunities for expanding Tapinator's gaming IP to new platforms such as Steam and leading messaging apps are also on the horizon. The company is targeting a 30+ percent annual bookings growth target for 2017-2019. Disclaimer

Tapinator, Inc. Blog

Tapinator, Inc. News:

Blockchain Emerging as a New Frontier for the Gaming Industry

Tapinator Introduces New Subsidiary Focused on Decentralized Blockchain Apps

NetworkNewsWire Announces Publication on M&A in the Mobile Gaming Industry

MGX Minerals Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals Inc. (MGXMF). Today, MGX Minerals Inc. closed trading at $0.9115, up 5.30%, on 542,828 volume with 245 trades. The stock’s average daily volume over the past 60 days is 176,682 and its 52-week low/high is $0.43/$2.119.

MGX Minerals Inc. (MGXMF) is pleased to announce wholly owned subsidiary ZincNyx Energy Solutions, Inc. (“ZincNyx”) has solved the long standing reliability issue caused by the growth of zinc dendrites in zinc-air flow batteries. The problem occurs when filaments of zinc (dendrites) grow in unintended areas and may cause membrane ruptures or short circuits to occur. The ZincNyx system is immune to this effect since it uses zinc dendrites as fuel and consumes them as part of its normal operation.

MGX Minerals Inc. (CSE: XMG) (FKT: 1MG) (OTCQB: MGXMF) is a diversified Canadian resource company developing large-scale mineral portfolios in specific commodities and jurisdictions in North America. The company controls significant interest in lithium, magnesium and silicon assets that offer streamlined development timelines and low capital expenditures. MGX Minerals and its engineering partner have developed a patent-pending, low-energy design process to extract valuable minerals from the abundant, highly mineralized brine wastewater produced each year by oil and gas companies.

This proprietary, petrolithium process rapidly concentrates lithium and other minerals from brine in less than a day. That's a stunning advancement from the conventional method of extracting minerals from brine through an evaporation process that can take up to 18 months, requires hundreds of acres of land, and averages less than a 50 percent mineral recovery rate. Using this advanced water purification technology, MGX Minerals cleans the wastewater that accompanies petroleum as it's being pulled up to the surface. The company's petrolithium process eliminates the need to inject contaminated wastewater back into the ground, which prevents drinking water contamination and possible earthquakes.

In January 2017, MGX Minerals successfully recovered concentrated lithium from heavy oil evaporator blowdown wastewater using its rapid recovery process, an accomplishment independently confirmed by the Saskatchewan Research Council. In August 2017, the company also successfully processed wastewater and lithium brine from eight North American projects at its one-cubic-meter-per-hour processing plant, proving the technology is economically viable. Research group Global Water Intelligence expects the wastewater treatment industry to grow into a $45 billion market annually by 2025, which suggests there are ample revenue-generating opportunities for MGX Minerals technology.

Lithium, the "white gold" of the new energy economy, is the key to clean energy development as global demand for hybrid and electric vehicles, high-drain portable electronic devices, and large-scale energy storage systems ramps up. Grand View Research, Inc. reports that the global lithium-ion battery market is expected to reach $93.1 billion by 2025. Current market forces show a high demand for lithium and a low supply, which further supports the necessity of MGX Mineral's cleaner, faster method of extracting high-value minerals from brine wastewater.

MGX Minerals is led by a team of industry standout performers who have worked in the mining and technology industries for decades. The leadership team is joined by an array of top-notch technical partners with unmatched experience in the oil and gas sectors, environmental services industry, marketing and product development, along with applied research and commercial development of technologies. Disclaimer

MGX Minerals Inc. Blog

MGX Minerals Inc. News:

MGX Minerals Announces Major Advancement in Mass Storage Battery Technology; Solves Zinc Dendrite Formation Limitation

MGX Minerals Announces 17.0 Metres of 1.81% Li2O at Case Lake Lithium Project

MGX Minerals Increases Ownership in Cleantech Engineering Partner PurLucid Treatment Solutions; Low Cost Nanofiltration Lithium Extraction System Nearing Deployment

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $2.02, off by 3.35%, on 429,102 volume with 538 trades. The stock’s average daily volume over the past 60 days is 464,427 and its 52-week low/high is $0.27/$2.54.

It’s no secret that cigarettes, a product whose toxins and carcinogens have shown time and again to cause illness and a long list of cancers, are addictive. Finding a way to stop smoking is an individual battle, although there is hope that new products are on the horizon that may help millions of people win the fight. Several significant research and development projects being undertaken by such innovators such as Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP) a company with proprietary technology capable of changing the way active pharmaceutical ingredients such as nicotine enter the body.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Intriguing Research into Pathways to Limit Nicotine, Quit Cigarette Use

OTC Markets Group Welcomes Lexaria Bioscience Corp. to OTCQX

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) and its Revolutionary Technology are Ready for the Cannabis Industry

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0848, off by 0.24%, on 7,720,046 volume with 627 trades. The stock’s average daily volume over the past 60 days is 11,418,310, and its 52-week low/high is $0.0105/$0.415.

The meteoric rise in the price of bitcoin in 2017, from just under $1,000 to above $15,000 at year-end, has attracted the attention of investors around the world. Powered by the blockchain, the distributed ledger technology which verifies transactions without the need for third-party validation, the cryptocurrency made great strides during the past year in achieving acceptance by businesses willing to accept it as a means of payment. Investors looking beyond bitcoin itself to find companies that stand to benefit from the growing usage of bitcoin for commercial transactions have a number of options to choose from, including SinglePoint, Inc. (SING).

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

Bitcoin’s Rise Speeds the Adoption of Cryptocurrency-Based Payment Solutions

NetworkNewsWire Releases Exclusive Audio Interview with SinglePoint, Inc. (SING)

MoneyTV with Donald Baillargeon, 1/5

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA). Today, Marijuana Company of America Inc. closed trading at $0.0549, off by 3.51%, on 19,828,360 volume with 1,066 trades. The stock’s average daily volume over the past 60 days is 14,494,979 and its 52-week low/high is $0.0181/$0.114.

Marijuana Company of America Inc. (MCOA) Director, Robert L. Hymers tapped as financial consultant and advisor for Cannabis Strategic Ventures, Inc. (OTC PINK: NUGS). Over the past few months, Cannabis Strategic has made great progress in organizing its business operations, vetting potential transactions and signing new business opportunities. Mr. Hymers will add an added level of financial experience to the Company that will be invaluable as the Company continues to expand.

Marijuana Company of America Inc. (MCOA) (the "Company") are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA's CEO, founded the first marijuana company ever to trade on a US stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing expotentially and consequently the founders of MCOA have contructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can also be used to produce products that are carbon neutral or even carbon negative, like the longest, strongest natural fiber on earth, building materials that are mold, pest and fire proof, super foods and so much more for additional business opportunities. No part of the plant is left unused and the Company's overall stategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented exponential growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015's $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal and cannabis and industrial hemp sectors. The Company's business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA's strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product "hempSMART Brain," is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience. Disclaimer

Marijuana Company of America Inc. Blog

Marijuana Company of America Inc. News:

Cannabis Strategic Ventures Welcomes Robert L. Hymers to the NUGS Family

Marijuana Company of America’s Overview of 2017 Highlights

Marijuana Company of America Launches New hempSMART™ Pain Product

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.049, off by 7.55%, on 13,116,622 volume with 553 trades. The stock’s average daily volume over the past 60 days is 12,141,344, and its 52-week low/high is $0.009/$0.16.

Global Payout, Inc. (GOHE) is pleased to announce that its majority owned subsidiary, MoneyTrac Technology, Inc. has executed a Sales and Marketing Management Agreement with High Grade Management Group, Inc. ("HGMG") to guide the development and implementation of a sales and marketing campaign to support the successful launch of HGMG's Apple Vapes products.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

MoneyTrac Technology, Inc. Teams Up with High Grade Management Group, Inc. for Sales and Marketing of Apple Vapes

CannabisNewsWire Announces Publication on Support Services for the Legal Cannabis Industry

Regulated Cannabis Industry Spawns Enterprises Providing a Diverse Array of Critical Support Services

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.71, off by 6.46%, on 127,512 volume with 103 trades. The stock’s average daily volume over the past 60 days is 236,711 and its 52-week low/high is $0.40/$2.75.

SmallCapVoice.com, Inc. (SCV) and ChineseInvestors.com, Inc. (OTCQB:CIIX) ('CIIX' or the 'Company'), the premier financial information website for Chinese-speaking investors, today announced that a new audio interview with the Company is now available. The interview can be heard at https://smallcapvoice.com/blog/1-5-18-smallcapvoice-interview-with-chineseinvestors-com-inc-ciix.

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

ChineseInvestor.com, Inc.'s CEO Warren Wang Provides Progress Report and Outlook for Investors in a New Audio Interview at SmallCapVoice.com

NetworkNewsWire Releases Exclusive Audio Interview with ChineseInvestors.com (CIIX)

CannabisNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Provides Post-Holiday Update on Baijiu Sales

Veritas Pharma, Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP)

The QualityStocks Daily Newsletter would like to spotlight Veritas Pharma, Inc. (VRTHF). Today, Veritas Pharma, Inc. closed trading at $0.6877, off by 6.42%, on 450,321 volume with 236 trades. The stock’s average daily volume over the past 60 days is 236,973 and its 52-week low/high is $0.22/$0.881.

Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP) provides the following statement to the memorandum issued by United States Attorney General Jeff Sessions on marijuana enforcement on January 4, 2018. Veritas believes that the memorandum dated January 4, 2018 issued by U.S. Attorney General Sessions, to repeal the Cole Memo, an Obama-era protection for States that have legalized marijuana is largely related to the recreational cannabis marketplace where individual States have allowed sales in the last twenty-four months. It does not affect the medical cannabis marketplace.

Veritas Pharma, Inc. (CSE: VRT) (OTCQB: VRTHF) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas' R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma's goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.

Veritas Pharma's management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.

Veritas Pharma's mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company's approach, combined with its strategic alliances, will effectively address the medical community's concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.

Veritas Pharma's clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.

Results of the company's research to date illustrate Veritas' unique place in the medical marijuana industry. The company's focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains. Disclaimer

Veritas Pharma, Inc. Blog

Veritas Pharma, Inc. News:

Veritas Pharma Provides Comment on U.S. Attorney General Jeff Sessions Memo

Veritas Pharma Provides Year End Update on Company’s Activities to Shareholders

Dr. Brian O’Connor Joins Veritas Pharma Advisory Board


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(KODK) +119.35%


Trader Power News
(PTIE) +103.15%


(WLYW) +75.00%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251